The case centers on the federal 340B program, in which drugmakers provide discounts to eligible healthcare providers that ...

The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...

Drugmaker Johnson and Johnson is suing the Department of Health and Human Services and the Health Resources and Services Administration for blocking its new 340B rebate model, and is seeking to verify ...

The aims of the 340B program are important. But, unfortunately, there is little evidence that the program is delivering on ...

Johnson & Johnson on Tuesday sued the Biden administration in a controversy over how it distributes rebates under the federal ...

Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...

The Medical University of South Carolina has been awarded $1.75 million from the Health Resources and Services Administration ...

Johnson & Johnson is escalating its fight with the federal government over its controversial plan to change how it doles out ...

In its lawsuit, the company argued that HRSA has wrongfully interpreted a federal law concerning the use of rebates in the 340B Drug Pricing Program. J&J recently sought to change payment terms for ...

A total of $11 million in grants to the University of Arkansas for Medical Sciences will allow it to expand clinical services ...

Despite rebukes by two federal circuit courts, an HHS sub-agency continues to overstep its authority when administering a ...

The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...